Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Verastem ( (VSTM) ) has provided an announcement.
On January 14, 2025, Verastem, Inc. exercised its option to acquire exclusive rights to develop and commercialize VS-7375, a selective KRAS G12D inhibitor, outside of certain Asian territories, from GenFleet Therapeutics. This strategic move is a significant step in Verastem’s expansion of its oncology pipeline, particularly in targeting RAS pathway driven cancers, potentially enhancing its competitive position in the biotech sector.
More about Verastem
Verastem, Inc. operates in the biotechnology industry, focusing on developing novel therapies for RAS/MAPK pathway driven cancers. The company primarily targets oncology programs and has established collaborations to enhance its drug development and commercialization capabilities.
YTD Price Performance: -16.95%
Average Trading Volume: 1,464,253
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $239.9M
For detailed information about VSTM stock, go to TipRanks’ Stock Analysis page.
